Instruction for use: Molgramostim

Trade name of the drug – Leucomax, Neustim

The Latin name of the substance Molgramostim

Molgramostimum (genus. Molgramostimi)

Chemical name

A highly purified water-soluble peptide consisting of 127 amino acid residues; Recombinant human granulocyte-macrophage colony-stimulating factor

Pharmacological group:

Stimulators of hematopoiesis

The nosological classification (ICD-10)

C90 Multiple myeloma and malignant plasma cell neoplasms: Retikuloplasmocytosis; Rustitsky's disease; Rustitskogo-Kahler's disease; Plasma cell myeloma; Myelomatosis

C91 Lymphoid leukemia [lymphatic leukemia]: Lymphatic leukemia; Lymphoproliferative diseases; Neuroleukemia; Refractory acute lymphoblastic leukemia; Refractory lymphoblastic leukemia; Transformation of preleukemias; Chronic lymphocytic leukemia; Lymphoproliferative disorders

D72 Other disorders of white blood cells: Lymphocytopenia; Hereditary neutropenia

Pharmacology

Mode action - Leukopoietic.

Stimulates the proliferation and differentiation of precursors, the content of mature cells in peripheral blood, the growth of granulocytes, monocytes and macrophages. Increases the functional activity of mature neutrophils - increases phagocytosis, increases the severity of the "respiratory explosion" (which provides the formation of 90% of active oxygen forms and is one of the most important mechanisms of phagocytosis), increases cytotoxicity against malignant cells. It has immunotropic activity, accelerates maturation of T-lymphocytes. It is able to enhance the expression of class II antigens HLA on monocytes and to increase the production of antibodies.

The time to reach Cmax is about 3 hours. T1 / 2 varies from 1 to 3 hours, depending on the mode of administration. Therapeutic effect occurs 2-4 days after the administration. With myelodysplastic syndromes, it effectively normalizes myelopoiesis. Reduces the recovery time of myeloid hematopoiesis after bone marrow transplantation in patients with acute leukemia, without affecting overall survival and time to relapse. Eliminates leukopenia after chemotherapy, reliably reducing the frequency of deep neutropenia and infectious complications, reduces the need for antibiotic therapy and provides an opportunity for intensification of chemotherapy. Increases the disease-free survival of patients with resistant lymphomas.

Application of the substance Molgramostim

Leukopenia in pathological conditions accompanied by violation of myelogenous hematopoiesis (including AIDS and other infectious diseases, myelodysplastic syndrome) or against antineoplastic chemotherapy, primary prevention of neutropenia and neutropenic infection at a high risk of its development after chemotherapy (for example, indication of the development of febrile Neutropenia during the first course of chemotherapy); To reduce the myelotoxic effect of antiviral drugs in the treatment of cytomegalovirus infection in AIDS patients, restore myeloid hematopoiesis in bone marrow transplantation; Stimulation of the release of hematopoietic precursor cells from the bone marrow to the peripheral blood for their subsequent isolation by leukapheresis and transplantation (preparation for antitumor chemotherapy with ultrahigh doses).

Contraindications

Hypersensitivity, myeloid leukemia, lung disease, autoimmune diseases, pregnancy, breast-feeding.

Side effects of the substance Molgramostim

An increase in body temperature, anorexia, dyspeptic phenomena, abdominal pain, stomatitis, dyspnea, weakness, sweating, ossalgia, myalgia, chest pain of a nonspecific character, convulsive syndrome, headaches, dizziness, fainting, paresis, increased intracranial pressure, Blood circulation, hypotension, arrhythmia, acute heart failure, exudative pleurisy, pericarditis, thrombocytopenia, eosinophilia, a decrease in albumin and hemoglobin level in the blood, allergic (skin rashes, angioedurot Edema, bronchospasm, anaphylactic shock) and local reactions.

Overdose

Symptoms (with chronic form): tachycardia, hypotension, fever, weakness, headaches, myalgia.

Treatment: symptomatic.

Routes of administration

SC, IV.

Precautions for the substance Molgramostim

Treatment should be carried out only in conditions of a specialized hospital (oncology, hematology, etc.). At the first administration of the drug should take into account the possibility of developing life-threatening allergic reactions. Continuous monitoring of peripheral blood (leukocytes, platelets, leukocyte formula, hemoglobin, hematocrit, albumin level) is necessary, with pulmonary diseases - a dynamic evaluation of the parameters of gas exchange and pulmonary ventilation. The identification of signs of serositis (pleurisy, pericarditis) requires immediate cancellation.